{
    "nctId": "NCT00458796",
    "briefTitle": "Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone",
    "officialTitle": "Cost-Effective Use of Bisphosphonates in Metastatic Bone Disease - A Comparison of Bone Marker Directed Zoledronic Acid Therapy to a Standard Schedule",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer, Musculoskeletal Complications, Pain",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 1500,
    "primaryOutcomeMeasure": "Fractures",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed primary breast cancer\n\n  * Advanced disease\n* Radiographic confirmation of bone metastases (\u2265 1 bone scan lesion must be confirmed as metastatic by plain radiographs or CT scan/MRI)\n\n  * Must have received zoledronic acid to treat metastatic bone disease (i.e., \u2265 4 or 5 zoledronic acid treatments prior to study entry for patients receiving 4- or 3-weekly infusions, respectively) for \u2265 4 months prior to study entry\n  * Any bisphosphonate to treat metastatic bone disease allowed provided it was not given for more than 12 months prior to study entry\n* No metabolic bone disease (e.g., Paget's disease of bone)\n\n  * Osteoporosis allowed\n* No brain metastases\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Male or female\n* Menopausal status not specified\n* WHO or ECOG performance status 0-2\n* Life expectancy \u2265 6 months\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* AST and ALT \u2264 3 times upper limit of normal (ULN)\n* Bilirubin \u2264 1.5 times ULN\n* Creatinine clearance \u2265 30 mL/min\n* No poor venous access\n* No concurrent active dental problems, including infection of the teeth or jawbone (maxilla or mandibular)\n* No prior or current diagnosis of osteonecrosis of the jaw\n* No other cancer within the past 5 years except nonmelanomatous skin cancer, carcinoma in situ of the uterine cervix, or superficial bladder cancer treated with curative intent\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No other prior bisphosphonate treatment within the past 3 weeks\n* No treatment with systemic bone-seeking radioisotopes (e.g., strontium chloride Sr 89, samarium Sm 153 lexidronam pentasodium) within the past 3 months\n* No wide-field (hemibody) radiotherapy within the past 3 months\n\n  * Recent standard-field, localized radiotherapy allowed\n* No dental or jaw surgery (e.g., extractions, implants) within the past 4 weeks\n* No other concurrent bisphosphonates\n* No concurrent medication with drugs known to affect bone metabolism (e.g., calcitonin or high-dose systemic corticosteroids \\[\\> 10 mg prednisolone/day or equivalent\\])\n\n  * Systemic or oral corticosteroids allowed for clearly indicated conditions (e.g., chemotherapy-induced emesis, brain metastases, compression syndromes)\n* Concurrent chemotherapy, biological therapy, or endocrine therapy allowed",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}